Aspiring TV writers can now apply for the next cycle of the Paramount Writers Mentoring Program, which has been newly ...

Dr. Barbara Wright, a Kansas City grant-writing expert with 30 years of experience and founder of Certified Dream Builder, ...

US President Donald Trump has issued a statement from the White House outlining four clear objectives for the ongoing US military operation against Iran on Monday (March 2, 2026). It was Trump's first ...

Trump has justified the war saying that Iran was attempting to rebuild its nuclear program Add as a preferred source on Google US President Donald Trump speaks during a Medal of Honor ceremony in the ...

President Trump said the ongoing strikes on Iran are the best chance to strike at its nuclear weapons program. But that's the same program he said, not long ago, was completely obliterated. President ...

Add Yahoo as a preferred source to see more of our stories on Google. Why did Trump attack Iran? Is the U.S. at war now? How long will this last? A complete FAQ on the new Mideast conflict. Trump ...

Trump Seeks to Justify Iran War, but Stated Objectives Shift By Nandita Bose, Humeyra Pamuk and Simon Lewis WASHINGTON, March 3 (Reuters) - U.S. President Donald Trump sought to justify a broad, ⁠open ...

At approximately 7:00 AM local time, the United States and Israel began conducting extensive strikes against a wide range of targets in Iran. The strikes have been dubbed Operation Epic Fury by the ...

This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...

FORT LEE, Va. — As service members prepare to navigate the unfamiliar terrain of post-service life, they don’t have to plot coordinates and determine azimuths alone. Fort Lee Transition Assistance ...

Courtney Peña-Lima is an associate director at the Biosciences Grant Writing Academy at Stanford University in California and a writing instructor at the Stanford University School of Medicine. Troy ...

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial ...